Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
By A. Khera, M. Chaffin, Krishna G. Aragam, Mary E. Haas, C. Roselli, S. Choi, P. Natarajan, Eric S. Lander, S. Lubitz, P. Ellinor and 1 more. 2018
2,683 citations recorded by the source corpus.
A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies. Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation1. Proposed clinical applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk. Although most disease risk is polygenic in nature2–5, it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations. Here, we develop and validate genome-wide polygenic scores for five common diseases. The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, respectively. For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk6. We propose that it is time to contemplate the inclusion of polygenic risk prediction in clinical care, and discuss relevant issues. Genome-wide polygenic risk scores derived from GWAS data for five common diseases can identify subgroups of the population with risk approaching or exceeding that of a monogenic mutation.
Subfields: Genetics, Pathology and Forensic Medicine, Computational Biology & Bioinformatics, Medical & Health AI
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Mark J. Daly
- Eric S. Lander
- Nicholas J. Timpson
- George Davey Smith
- Andrew E. Teschendorff
- Nicholas J. Schork
- Caroline Relton
- Alicia R. Martin
In Pathology and Forensic Medicine
In Computational Biology & Bioinformatics
In Medical & Health AI
Citations in the corpus
- Adaptive Sampling Strategies to Construct Equitable Training Datasets (2022, background): “PRSs have been found to be predictive for many complex genetic diseases such as coronary artery disease and Type 2 diabetes [39], and are believed to be promising tools for risk stratification for health interventions more broadly.”
- ARTIFICIAL INTELLIGENCE AND PERSONALIZED MEDICINE (2019, background): “[86–88] In addition, by combining insights into genetic predisposition to disease with continuous monitoring to identify early signs of disease, one could potentially stop diseases in their tracks before complicated treatments are needed for fulminant forms of the disease manifest.”
- Development and Standardization of an Improved Type 1 Diabetes Genetic Risk Score for Use in Newborn Screening and Incident Diagnosis (2019, background): “Genome-wide risk scores have recently been very effective at improving prediction of non–HLA-linked disease (33), but the extremely strong HLA bias of T1D heritability, and the inability of these models to currently analyze the HLA region, means that these methods are less suitable for T1D predictio”
- Polygenic prediction of weight and obesity trajectories from birth to adulthood (2019, background): “Obtaining meaningful predictive power thus requires aggregating information from many common variants into a polygenic score (Chatterjee et al., 2016; Khera et al., 2018).”